Skip to content

Evaluating the Durability of Closure for Venous Leg Ulcers

Prospective Multicenter Observational Study Evaluating the Durability of Closure for Venous Leg Ulcers Following a Randomized, Controlled, Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06697925
Acronym
THORSDOTTIR
Enrollment
150
Registered
2024-11-20
Start date
2025-01-31
Completion date
2026-12-31
Last updated
2025-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Leg, Venous Leg Ulcer, Venous Leg Ulcer (VLU), Venous Ulcer, VLU

Brief summary

The goal of this observational study is to determine the durability of closure for venous leg ulcer subjects that achieved closure in the THOR trial.

Detailed description

To determine durability of closure (rate of target wound recurrence) of subjects with a closed venous leg ulcer during the THOR clinical trial comparing subjects treated with Intact Fish Skin Graft (IFSG) plus standard of care (SOC) to subjects treated with SOC alone.

Interventions

None listed

Sponsors

Serena Group
CollaboratorOTHER
Kerecis Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\. Subjects must have participated in the THOR trial and achieved complete closure by the 12-week endpoint.

Exclusion criteria

* 1\. Subjects who did not participate in the THOR trial. 2. Subjects who participated in the THOR trial and did not achieve complete closure.

Design outcomes

Primary

MeasureTime frameDescription
Durability of closure12-month follow-upTo demonstrate durability of closure (rate of target wound recurrence) of subjects with a closed venous leg ulcer during the THOR clinical trial comparing subjects treated with Intact Fish Skin Graft (IFSG) plus standard of care (SOC) to subjects treated with SOC alone.

Countries

United States

Contacts

Primary ContactBennett Rogers
brogers@serenagroups.com888-960-1343
Backup ContactThomas Serena, MD
tserena@serenagroups.com814-688-4000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026